who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How Regeneron Pharmaceuticals (REGN) makes money: Q3 2026 revenue breakdown

US GAAP, Q3 2026 · quarter ended 09/30/2026 · released Oct 30

Net income

$1,949M

up 33.5% y/y

Total revenues

$5,116M

up 36.3% y/y

Income from operations

$2,048M

up 99.5% y/y

Next report

~ Jan 29

not announced yet

The quarter in brief

Q3 2026 revenue rose 36% to $5.1 billion and operating income nearly doubled to $2,048.2 million from $1,026.8 million. GAAP net income grew 33% to $1,948.7 million and diluted EPS rose 35% to $18.45.

Key growth driver: Collaboration revenue — the fastest-growing revenue line: $3,001, +52% y/y. · by the Q3 2026 report

How does Regeneron Pharmaceuticals make money?

Regeneron Pharmaceuticals brought in $5.12 billion of revenue in Q3 2026, up 36.3% year over year. The largest source was Collaboration revenue: $3.00 billion, or 59% of the total, followed by Net product sales ($1.81B, 35%); other lines add the remaining 6%. Net income for the quarter was $1.95 billion, up 33.5% year over year.

Revenue by source, Q3 2026
  • Collaboration revenue$3.00B · 59% · +52.4%
  • Net product sales$1.81B · 35% · +13.7%
  • Other revenue$310M · 6% · +56.4%

Shares of $5.12B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of REGN (Regeneron Pharmaceuticals) earnings report for Q3 2026: revenue, costs and profitNet product sales$1,805 · +13.7%Collaboration revenue$3,001 · +52.4%Other revenue$310 · +56.4%Total revenues$5,116 · +36.3%Cost of goodssold$322 · +14.5%Cost ofcollaboration andcontractmanufacturing$252 · +4.7%Research anddevelopment$1,795 · +21.7%Acquiredin-processresearch anddevelopment$21.5 · −74.1%Selling, general,andadministrative$678 · +3.0%Income fromoperations$2,048 · +99.5%40.0% marginOther income(expense), net$247 · −67.4%Interest expense$10.6 · −45.1%Income beforeincome taxes$2,284 · +29.5%Income tax expense$335 · +10.6%14.7% effective rateNet income$1,949 · +33.5%$18.45/sh · 38.1% margin
Sankey diagram of REGN (Regeneron Pharmaceuticals) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Net product sales$1,805 · +13.7%
Collaboration revenue$3,001 · +52.4%
Other revenue$310 · +56.4%
Total revenues$5,116 · +36.3%
Cost of goods sold$322 · +14.5%
Cost of collaboration and contract manufacturing$252 · +4.7%
Research and development$1,795 · +21.7%
Acquired in-process research and development$21.5 · −74.1%
Selling, general, and administrative$678 · +3.0%
Income from operations$2,048 · +99.5% · 40.0% margin
Other income (expense), net$247 · −67.4%
Interest expense$10.6 · −45.1%
Income before income taxes$2,284 · +29.5%
Income tax expense$335 · +10.6% · 14.7% effective rate
Net income$1,949 · +33.5% · $18.45/sh · 38.1% margin

Verdict: Q3 2026 revenue rose 36% to $5.1 billion and operating income nearly doubled to $2,048.2 million from $1,026.8 million. GAAP net income grew 33% to $1,948.7 million and diluted EPS rose 35% to $18.45.

Full-year 2026 guidance was updated: GAAP R&D to $6.600–$6.735 billion, GAAP SG&A to $2.730–$2.860 billion, GAAP gross margin on net product sales to approximately 80% and GAAP effective tax rate to approximately 14%. In the first nine months of 2026 the company repurchased $2.3 billion of stock, with $2.2 billion remaining authorized, and declared a dividend of $0.94 per share payable on December 3, 2026. A $1.0 billion up-front payment from the expanded Sanofi collaboration will be recognized as collaboration revenue in Q4 2026.

Source and notation

Source: Regeneron Pharmaceuticals press release, 8-K EX-99.1 of 10/30/2026 (SEC EDGAR).

Open as an image: Regeneron Pharmaceuticals (REGN), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Regeneron Pharmaceuticals (REGN) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/regn. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/regn"><img src="https://whoreportstoday.com/t/regn/img/regeneron-pharmaceuticals-regn-earnings-sankey.png" alt="Regeneron Pharmaceuticals (REGN) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/regn">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/regn/img/regeneron-pharmaceuticals-regn-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/regn">Regeneron Pharmaceuticals (REGN) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Company reports

Q3 2026latest breakdownQ3 2026 revenue rose 36% to $5.1 billion and operating income nearly doubled to $2,048.2 million from $1,026.8 million…
Q2 2026A strong top-line quarter — revenue up 17% on surging Sanofi/Dupixent collaboration profits and EYLEA HD growth — but…

Company guidance

Same quarter a year ago (ended December 31, 2025): revenue $3.884B, EPS (GAAP) $7.78

How we calculate

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

REGN earnings history: past report dates

Oct 30, 2026 Fri6:50 ambefore market openSep 30, 2026$5.1B+36% y/y$18.45+35% y/y
Jul 30, 2026 Thu6:48 ambefore market openJun 30, 2026$4.3B+17% y/y$12.23−5% y/y
Apr 29, 2026 Wed6:50 ambefore market openMar 31, 2026$3.6B+19% y/y$6.75−7% y/y
Jan 30, 2026 Fri6:51 ambefore market openDec 31, 2025≈$3.9B+3% y/y≈$7.78−4% y/y
Oct 28, 2025 Tue6:50 ambefore market openSep 30, 2025$3.8B+1% y/y$13.62+18% y/y
Aug 1, 2025 Fri6:49 ambefore market openJun 30, 2025$3.7B+4% y/y$12.81+3% y/y
Apr 29, 2025 Tue6:37 ambefore market openMar 31, 2025$3.0B−4% y/y$7.27+16% y/y
Feb 4, 2025 Tue7:11 ambefore market openDec 31, 2024≈$3.8B+10% y/y≈$8.12−20% y/y
Oct 31, 2024 Thu7:10 ambefore market openSep 30, 2024$3.7B+11% y/y$11.54+30% y/y
Aug 1, 2024 Thu7:06 ambefore market openJun 30, 2024$3.5B+12% y/y$12.41+46% y/y
May 2, 2024 Thu7:06 ambefore market openMar 31, 2024$3.1B−1% y/y$6.27−13% y/y
Feb 2, 2024 Fri7:16 ambefore market openDec 31, 2023≈$3.4B+1% y/y≈$10.21−3% y/y
Nov 2, 2023 Thu7:10 ambefore market openSep 30, 2023$3.4B+15% y/y$8.89−24% y/y
Aug 3, 2023 Thu6:48 ambefore market openJun 30, 2023$3.2B+11% y/y$8.50+14% y/y
Show all 14 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Regeneron Pharmaceuticals: 15-year financials

202514,3433,5784,5054,081370
202414,2023,9914,4133,6650
202313,1174,0473,9543,8750
202212,1734,7394,3384,425—
202116,0728,9478,0756,529—
20208,4973,5773,5132,004—
20196,5582,2102,1162,000—
20185,1462,5342,4441,812—
20175,8722,0801,1991,035—
20164,8601,331896974—
20154,1041,252636653—
20142,820824338419—
20132,105743414432—
20121,379458750−124—
2011446−205−222−199—

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Regeneron Pharmaceuticals: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202540,55931,2571,9863,11818,0224,368
202437,75929,3541,9842,48818,6613,944
202333,08025,9731,9832,73019,4793,423
202229,21522,6641,9813,10615,8843,141
202125,43518,7691,9802,88614,0153,933
202017,16311,0251,9792,1949,7792,697
201914,80511,09001,6187,6892,097
201811,7358,757—1,4686,4481,443
20178,7646,144—8134,3351,136
20166,9744,449—5353,1801,242
20155,6093,655—8092,915811
20143,8382,550—6492,085655
20132,9511,965—5361,797299
20122,0811,257—2301,206164
20111,324486—484666148

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated3,6753,808−133
· incl. D&A (non-cash add-back)depreciation & amortization368399
· incl. stock-based comp (non-cash)share-based compensation756744
Capexpurchases of property & equipment−771−650−121
Free cash flow ≈operating cash flow − capex2,9043,159−254
Investing activities, netcapex, acquisitions, securities−810−849+39.7
· incl. acquisitionsbusinesses net of cash acquired0−3+3
Financing activities, netdebt, buybacks, dividends−2,317−2,935+618
· incl. buybacksrepurchases of common stock−2,363−2,767+404
· incl. dividends paid−290−278−12.7
FX effect on cash−0.70.6−1.3
Net change in cash54824.1+524
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $33.5B (75% of total assets). Compare with other S&P 500 companies →

Corporate governance

1.5/2mostly good

  • Feb 20262025 10-K: Class A holders have 10 votes per share and 14.9% of total voting power as of December 31, 2025; 1.82M Class A and 103.9M common shares outstanding. sec.gov ↗
  • Feb 2026Diluted shares −5.7% over 2020–2025; $3.44B buyback in 2025; SBC 6.9% of revenue. data.sec.gov ↗
2 more facts and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Feb 2021In May 2020, the company bought 9.8M shares from Sanofi for $5B alongside a secondary offering; Sanofi was bound by a standstill and could not control the company. sec.gov ↗
  • Feb 2026A securities class action was filed in January 2025 and has not been settled; the DOJ False Claims Act cases concern Eylea sales. sec.gov ↗

Scoring: 2.0 −0.5 (criterion 7: Class A with 10 votes per share — 14.9% of voting power held by pre-IPO holders, short of a majority) = 1.5

Share classes
Common Stock (one vote) and Class A Stock (10 votes; 1.82M shares held by pre-IPO holders, including CEO Schleifer): 14.9% of voting power as of December 31, 2025, no majority → −0.5 (criterion 7).
Dilution
Diluted shares −5.7% over 2020–2025; SBC 6.9% of revenue (<10%) — no deduction.
Disclosure
Full reporting, no violations.
Dividends
Dividends introduced for the first time in 2025; policy not breached.
Lawsuits & regulators
Securities class action (January 2025) not settled; DOJ civil False Claims Act cases (Eylea) do not concern investor disclosure; no SEC cases.
Related parties
Repurchase of 9.8M shares from Sanofi for $5B (May 2020) at the secondary offering price; Sanofi did not control the company (standstill) → no deduction; transactions with Schleifer's foundation ~$0.12M — immaterial.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies with no net debt

Regeneron Pharmaceuticals (REGN) earnings: FAQ

How does Regeneron Pharmaceuticals make money?

Regeneron Pharmaceuticals brought in $5.12 billion of revenue in Q3 2026, up 36.3% year over year. The largest source was Collaboration revenue: $3.00 billion, or 59% of the total, followed by Net product sales ($1.81B, 35%); other lines add the remaining 6%. Net income for the quarter was $1.95 billion, up 33.5% year over year.

When is REGN's next earnings date?

We have not yet seen an announcement of the date from Regeneron Pharmaceuticals (REGN). Based on last year's report on Jan 30, 2026, the next report is expected around Jan 29, 2027.

What time does REGN report earnings?

Regeneron Pharmaceuticals usually reports before market open: its latest results release was filed with the SEC at 6:50 am ET on Oct 30, 2026.

When did REGN last report earnings?

Regeneron Pharmaceuticals reported Q3 2026 results on Oct 30, 2026.

Where can I find Regeneron Pharmaceuticals's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to REGN's filings; this page breaks the latest report down in a Sankey chart.

What was REGN's net income in Q3 2026?

Regeneron Pharmaceuticals reported net income of $1,949M for Q3 2026 (+33.5% year over year), under US GAAP.

Does Regeneron Pharmaceuticals pay dividends?

Yes. In 2025, Regeneron Pharmaceuticals paid $370M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Regeneron Pharmaceuticals's revenue changed since 2011?

Per its 10-K filings, revenue grew 32.2x: $446M in 2011 and $14,343M in 2025. The peak was $16,072M in 2021. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · TECH · Q4 FY2026 · TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy